Shmuel A. Ben-Sasson
Corporate Officer/Principal bei The Hebrew University of Jerusalem
Profil
Shmuel A.
Ben-Sasson is the founder of Chiasma, Inc. (founded in 2001) and Raziel Therapeutics RT Ltd.
(founded in 2012).
Dr. Ben-Sasson is also the founder of Keryx Biopharmaceuticals, Inc. Currently, Dr. Ben-Sasson holds the position of Associate Professor-Experimental Medicine at The Hebrew University of Jerusalem.
Aktive Positionen von Shmuel A. Ben-Sasson
| Unternehmen | Position | Beginn |
|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Shmuel A. Ben-Sasson
| Unternehmen | Position | Ende |
|---|---|---|
| CHIASMA, INC. | Gründer | - |
Raziel Therapeutics RT Ltd.
 Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | Gründer | - |
| KERYX BIOPHARMACEUTICALS | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Chiasma, Inc.
 Chiasma, Inc. Pharmaceuticals: MajorHealth Technology Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. Its products include octreotide capsules. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin in 2001 and is headquartered in Needham, MA. | Health Technology |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | Health Technology |
